RU2284327C2 - Имидазоло-5-ил-2-анилинопиримидины как агенты для ингибирования пролиферации клеток, способ их получения (варианты), применение, фармацевтическая композиция, способ продуцирования - Google Patents

Имидазоло-5-ил-2-анилинопиримидины как агенты для ингибирования пролиферации клеток, способ их получения (варианты), применение, фармацевтическая композиция, способ продуцирования Download PDF

Info

Publication number
RU2284327C2
RU2284327C2 RU2003109612/04A RU2003109612A RU2284327C2 RU 2284327 C2 RU2284327 C2 RU 2284327C2 RU 2003109612/04 A RU2003109612/04 A RU 2003109612/04A RU 2003109612 A RU2003109612 A RU 2003109612A RU 2284327 C2 RU2284327 C2 RU 2284327C2
Authority
RU
Russia
Prior art keywords
sulfamoyl
alkyl
formula
compound
pharmaceutically acceptable
Prior art date
Application number
RU2003109612/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2003109612A (ru
Inventor
Глори Анн БРО (GB)
Глория Анн БРО
Николас Джон НЬЮКОМ (GB)
Николас Джон НЬЮКОМ
Эндрю Питер ТОМАС (GB)
Эндрю Питер Томас
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9898838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2284327(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2003109612A publication Critical patent/RU2003109612A/ru
Application granted granted Critical
Publication of RU2284327C2 publication Critical patent/RU2284327C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
RU2003109612/04A 2000-09-05 2001-08-30 Имидазоло-5-ил-2-анилинопиримидины как агенты для ингибирования пролиферации клеток, способ их получения (варианты), применение, фармацевтическая композиция, способ продуцирования RU2284327C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0021726.5A GB0021726D0 (en) 2000-09-05 2000-09-05 Chemical compounds
GB0021726.5 2000-09-05

Publications (2)

Publication Number Publication Date
RU2003109612A RU2003109612A (ru) 2004-12-10
RU2284327C2 true RU2284327C2 (ru) 2006-09-27

Family

ID=9898838

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003109612/04A RU2284327C2 (ru) 2000-09-05 2001-08-30 Имидазоло-5-ил-2-анилинопиримидины как агенты для ингибирования пролиферации клеток, способ их получения (варианты), применение, фармацевтическая композиция, способ продуцирования

Country Status (32)

Country Link
US (2) US6969714B2 (OSRAM)
EP (1) EP1351958B1 (OSRAM)
JP (1) JP3523641B2 (OSRAM)
KR (1) KR100802368B1 (OSRAM)
CN (1) CN1269813C (OSRAM)
AR (1) AR033836A1 (OSRAM)
AT (1) ATE269327T1 (OSRAM)
AU (2) AU2001284192B2 (OSRAM)
BG (1) BG107579A (OSRAM)
BR (1) BR0113496A (OSRAM)
CA (1) CA2417148C (OSRAM)
CZ (1) CZ2003617A3 (OSRAM)
DE (1) DE60103935T2 (OSRAM)
DK (1) DK1351958T3 (OSRAM)
EE (1) EE05430B1 (OSRAM)
ES (1) ES2221904T3 (OSRAM)
GB (1) GB0021726D0 (OSRAM)
HU (1) HUP0302922A3 (OSRAM)
IL (1) IL154292A0 (OSRAM)
IS (1) IS2055B (OSRAM)
MX (1) MXPA03001511A (OSRAM)
MY (1) MY127126A (OSRAM)
NO (1) NO324059B1 (OSRAM)
NZ (1) NZ523787A (OSRAM)
PL (1) PL360627A1 (OSRAM)
PT (1) PT1351958E (OSRAM)
RU (1) RU2284327C2 (OSRAM)
SK (1) SK287277B6 (OSRAM)
TW (1) TWI242559B (OSRAM)
UA (1) UA74206C2 (OSRAM)
WO (1) WO2002020512A1 (OSRAM)
ZA (1) ZA200300612B (OSRAM)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
JP2005524672A (ja) 2002-03-09 2005-08-18 アストラゼネカ アクチボラグ Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体
GB0205690D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0311276D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
MX2007004488A (es) 2004-10-13 2007-09-11 Wyeth Corp Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos.
CN101083996A (zh) * 2004-10-28 2007-12-05 Irm责任有限公司 作为hedgehog途径调节剂的化合物和组合物
WO2006064251A1 (en) * 2004-12-17 2006-06-22 Astrazeneca Ab 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors
CN1939910A (zh) * 2004-12-31 2007-04-04 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
GB0504753D0 (en) * 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
CA2617170A1 (en) 2005-07-30 2007-02-08 Astrazeneca Ab Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
US7745428B2 (en) * 2005-09-30 2010-06-29 Astrazeneca Ab Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
UY29827A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
EP1942897A1 (en) * 2005-10-03 2008-07-16 AstraZeneca AB Use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
WO2007129019A1 (en) * 2006-04-21 2007-11-15 Astrazeneca Ab Sulfonamide compounds useful as edg receptor modulators
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
US20100240686A1 (en) 2006-06-21 2010-09-23 Clifford Jones Chemical compounds
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
TW200815417A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II
US20110003691A1 (en) * 2008-03-14 2011-01-06 Basf Se Substituted Pyrazinylmethyl Sulfonamides For Use As Fungicides
WO2010009139A2 (en) * 2008-07-14 2010-01-21 Gilead Colorado, Inc. Imidazolyl pyrimidine inhibitor compounds
CN101503402B (zh) * 2009-03-10 2014-06-25 沈阳药科大学 2-苯胺嘧啶衍生物及其制备和用途
CA2761064A1 (en) 2009-04-15 2010-10-21 Astrazeneca Ab Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease
MX2012014158A (es) 2010-06-04 2013-02-07 Hoffmann La Roche Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2).
ES2653967T3 (es) 2010-11-10 2018-02-09 Genentech, Inc. Derivados de pirazol aminopirimidina como moduladores de LRRK2
CN106928192B (zh) * 2015-12-29 2020-11-13 中国科学院广州生物医药与健康研究院 一种嘧啶类化合物及其制备方法和应用
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
PH12022550361A1 (en) 2019-08-14 2023-02-27 Incyte Corp Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
IL303237A (en) * 2020-11-27 2023-07-01 Anrui Biomedical Tech Guangzhou Co Ltd Aminoheteroaryl kinase inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CN113999210B (zh) * 2021-12-03 2023-05-23 郑州大学第一附属医院 一组2-苯氨基-4-三氮唑基嘧啶类衍生物及其应用
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN116751167B (zh) * 2023-07-03 2025-09-23 苏州诚和医药化学有限公司 一种(e)-4-(1-苄基-2-甲基-1h-咪唑-5-基)-3-(乙氧基酰基)丁-3-烯酸的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859041A (en) * 1996-06-10 1999-01-12 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
WO1999032121A1 (en) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
RU2140918C1 (ru) * 1993-06-16 1999-11-10 Смитклайн Бичам Корпорейшн Три-замещенные имидазолы, обладающие терапевтическими свойствами, способ получения, фармацевтическая композиция, способ лечения
WO2000026209A1 (en) * 1998-11-03 2000-05-11 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659363A (en) 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
US4946956A (en) 1988-09-21 1990-08-07 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US4983608A (en) * 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
DK0664291T3 (da) * 1992-10-05 2000-10-30 Ube Industries Pyrimidinforbindelse
ATE325113T1 (de) 1993-10-01 2006-06-15 Novartis Pharma Gmbh Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
DK0672041T3 (da) 1993-10-01 2002-02-25 Novartis Ag Farmakologisk aktive pyridinderivater og fremgangsmåder til fremstilling deraf
WO1995009847A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
US5494998A (en) 1994-11-14 1996-02-27 Akzo Nobel N.V. Polymerization of carbon monoxide and ethylene using catalyst containing non-coordinating, non-acidic anion
DK0813525T3 (da) 1995-03-10 2004-02-16 Berlex Lab Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP2000507558A (ja) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
JP2000511883A (ja) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
AU5147598A (en) 1996-10-17 1998-05-11 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
DE19710435A1 (de) 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
AU734009B2 (en) 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
SK286940B6 (sk) 1997-06-12 2009-07-06 Aventis Pharma Limited Spôsob prípravy imidazolového derivátu
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
WO1999018096A1 (en) 1997-10-02 1999-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1021173A1 (en) 1997-10-10 2000-07-26 Imperial College Innovations Limited Use of csaid?tm compounds for the management of uterine contractions
JP4135318B2 (ja) 1997-12-15 2008-08-20 アステラス製薬株式会社 新規なピリミジン−５−カルボキサミド誘導体
CA2321153A1 (en) 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
DK0945443T3 (da) 1998-03-27 2003-06-02 Janssen Pharmaceutica Nv HIV-hæmmende pyrimidinderivater
GB9806739D0 (en) 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
ES2270612T3 (es) 1998-08-29 2007-04-01 Astrazeneca Ab Compuestos de pirimidina.
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
SK3852001A3 (en) 1998-09-18 2003-03-04 Basf Ag 4-Aminopyrrolopyrimidines as kinase inhibitors
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6627633B2 (en) 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
EP1224185B1 (en) 1999-10-27 2005-11-30 Novartis AG Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use
IL149150A0 (en) * 1999-11-22 2002-12-01 Smithkline Beecham Plc 2-(4-(6-methoxy-naphthalene-2-yl)-5-pyridin-4-yl-1h-imidazole-2-yl)-2-methyl-derivatives, pharmaceutical compositions comprising them and use thereof as tie2 receptor kinase inhibitors
DE60043397D1 (de) 1999-12-28 2010-01-07 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
JP2005511608A (ja) * 2001-11-07 2005-04-28 エフ．ホフマン−ラ　ロシュ　アーゲー アミノピリミジン類及び−ピリジン類

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2140918C1 (ru) * 1993-06-16 1999-11-10 Смитклайн Бичам Корпорейшн Три-замещенные имидазолы, обладающие терапевтическими свойствами, способ получения, фармацевтическая композиция, способ лечения
US5859041A (en) * 1996-06-10 1999-01-12 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
WO1999032121A1 (en) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
WO2000026209A1 (en) * 1998-11-03 2000-05-11 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles

Also Published As

Publication number Publication date
DE60103935D1 (de) 2004-07-22
EP1351958B1 (en) 2004-06-16
NO20031006L (no) 2003-03-04
UA74206C2 (uk) 2005-11-15
AU8419201A (en) 2002-03-22
EE05430B1 (et) 2011-06-15
MXPA03001511A (es) 2003-06-09
KR20030027109A (ko) 2003-04-03
ATE269327T1 (de) 2004-07-15
JP2004508365A (ja) 2004-03-18
AU2001284192B2 (en) 2006-10-26
IL154292A0 (en) 2003-09-17
WO2002020512A9 (en) 2004-05-06
BG107579A (bg) 2003-10-31
PT1351958E (pt) 2004-09-30
HK1057553A1 (en) 2004-04-08
SK287277B6 (sk) 2010-05-07
CN1269813C (zh) 2006-08-16
ES2221904T3 (es) 2005-01-16
IS6715A (is) 2003-02-12
CZ2003617A3 (cs) 2003-06-18
BR0113496A (pt) 2003-07-01
EE200300088A (et) 2005-02-15
TWI242559B (en) 2005-11-01
US20060004033A1 (en) 2006-01-05
ZA200300612B (en) 2004-04-22
US20040014776A1 (en) 2004-01-22
EP1351958A1 (en) 2003-10-15
PL360627A1 (en) 2004-09-20
GB0021726D0 (en) 2000-10-18
NZ523787A (en) 2004-09-24
HUP0302922A3 (en) 2007-02-28
NO20031006D0 (no) 2003-03-04
HUP0302922A2 (hu) 2003-12-29
JP3523641B2 (ja) 2004-04-26
CN1452620A (zh) 2003-10-29
SK2412003A3 (en) 2003-09-11
NO324059B1 (no) 2007-08-06
CA2417148A1 (en) 2002-03-14
DE60103935T2 (de) 2005-07-21
DK1351958T3 (da) 2004-09-06
AR033836A1 (es) 2004-01-07
CA2417148C (en) 2010-09-21
KR100802368B1 (ko) 2008-02-13
US6969714B2 (en) 2005-11-29
MY127126A (en) 2006-11-30
IS2055B (is) 2005-10-14
WO2002020512A1 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
RU2284327C2 (ru) Имидазоло-5-ил-2-анилинопиримидины как агенты для ингибирования пролиферации клеток, способ их получения (варианты), применение, фармацевтическая композиция, способ продуцирования
RU2299201C2 (ru) Производные пиримидина, способ их получения (варианты), фармацевтические композиции (варианты) и способ ингибирования
RU2248976C2 (ru) Имидазо[1,2-а]пиридиновые и пиразол[2,3-а]пиридиновые производные
JP3569524B1 (ja) 化合物
AU2001284192A1 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
NZ555474A (en) 4-(4-(imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors
JP2006528962A (ja) ２−アニリノ−４−（イミダゾール−５−イル）−ピリミジン誘導体、および、ｃｄｋ（ｃｄｋ２）阻害剤としてのそれらの使用
JP4433797B2 (ja) ピリミジン化合物
HK1057553B (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120831